Drug Profile
Research programme: recombinant fibrinolysin - Grifols
Alternative Names: Delta (K2-K5) plasmin; rPlasmin; TAL 6003Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Grifols
- Developer Bausch & Lomb; Grifols
- Class Serine endopeptidases; Thrombolytics
- Mechanism of Action Fibrinolysis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Stroke; Thrombosis
- Discontinued Eye disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Stroke in USA (Parenteral)
- 14 Jun 2012 Preclinical development is ongoing in USA for transient ischaemic stroke
- 14 Jun 2012 No development reported - Preclinical for Thrombosis in USA (Parenteral)